(Q43041256)

English

Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy

scientific article published in November 2007

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 November 2017

Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy (English)

1 reference

Europe PubMed Central

12 November 2017

pegylated interferon

1 reference

based on heuristic

inferred from title

author name string

J Koirala

1

1 reference

Europe PubMed Central

12 November 2017

S D Gandotra

2

1 reference

Europe PubMed Central

12 November 2017

S Rao

3

1 reference

Europe PubMed Central

12 November 2017

G Sangwan

4

1 reference

Europe PubMed Central

12 November 2017

A Mushtaq

5

1 reference

Europe PubMed Central

12 November 2017

T H Htwe

6

1 reference

Europe PubMed Central

12 November 2017

A Adamski

7

1 reference

Europe PubMed Central

12 November 2017

D Blessman

8

1 reference

Europe PubMed Central

12 November 2017

N M Khardori

9

1 reference

Europe PubMed Central

12 November 2017

publication date

1 November 2007

1 reference

Europe PubMed Central

12 November 2017

Journal of Viral Hepatitis

1 reference

Europe PubMed Central

12 November 2017

14

1 reference

Europe PubMed Central

12 November 2017

782-787

1 reference

Europe PubMed Central

12 November 2017

11

1 reference

Europe PubMed Central

12 November 2017

Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

Side effects of therapy of hepatitis C and their management

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

Premature discontinuation of interferon plus ribavirin for adverse effects: a multicentre survey in 'real world' patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

Natural history of hepatitis C following liver transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

Role of epoetin alfa in maintaining ribavirin dose

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

Hematologic disorders associated with hepatitis C virus infection and their management

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

Cost-effectiveness of growth factors during hepatitis C anti-viral therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

Hematologic side effects of interferon and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

Predictors for hematopoietic growth factors use in HIV/HCV-coinfected patients treated with peginterferon alfa 2b and ribavirin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

RANDOMIZED CONTROLLED TRIAL OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR FOR THE TREATMENT OF CHRONIC HEPATITIS C

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2007.00870.X

21 January 2018

Identifiers

10.1111/J.1365-2893.2007.00870.X

1 reference

Europe PubMed Central

12 November 2017

1 reference

Europe PubMed Central

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43041256&oldid=1978324165"